雜志介紹

Biodrugs雜志介紹

《Biodrugs》是(shi)一本(ben)(ben)以(yi)English為(wei)主(zhu)的(de)(de)(de)未開放獲(huo)取國際優秀(xiu)期刊，中文名稱(cheng)生物(wu)藥物(wu)，本(ben)(ben)刊主(zhu)要出版、報道醫(yi)學-PHARMACOLOGY & PHARMACY領(ling)域(yu)(yu)的(de)(de)(de)研究(jiu)動態以(yi)及在(zai)該(gai)領(ling)域(yu)(yu)取得的(de)(de)(de)各方(fang)面的(de)(de)(de)經驗(yan)和科(ke)研成果，介紹該(gai)領(ling)域(yu)(yu)有關本(ben)(ben)專業的(de)(de)(de)最(zui)新(xin)(xin)進(jin)展(zhan)(zhan)，探討行業發(fa)展(zhan)(zhan)的(de)(de)(de)思路和方(fang)法，以(yi)促進(jin)學術信息交流，提高行業發(fa)展(zhan)(zhan)。該(gai)刊已被國際權威數據庫(ku)SCIE收錄(lu)，為(wei)該(gai)領(ling)域(yu)(yu)相(xiang)關學科(ke)的(de)(de)(de)發(fa)展(zhan)(zhan)起到(dao)了(le)良好的(de)(de)(de)推動作用，也得到(dao)了(le)本(ben)(ben)專業人員的(de)(de)(de)廣泛認(ren)可(ke)。該(gai)刊最(zui)新(xin)(xin)影響因子為(wei)5.4，最(zui)新(xin)(xin)CiteScore 指數為(wei)12.6。

本刊近期(qi)中國學者(zhe)發表的(de)論文主要有：

• Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial

  Author: Wu, Min; Li, Xiaojiao; Yang, Deming; Wang, Meng; Zhang, Hong; Li, Cuiyun; Mai, Jiajia; Yang, Lizhi; Qi, Yunpeng; Yu, Jin-Chen; Yang, Xiaolei; Wang, Zhaohe; Gu, Cailing; Ding, Yanhua

• Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

  Author: Jiang, Yuxiong; Chen, Youdong; Yu, Qian; Shi, Yuling

• Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines

  Author: Ou, Bingming; Yang, Ying; Lv, Haihui; Lin, Xin; Zhang, Minyu

• Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

  Author: Li, Huiping; Huang, Yan; Chen, Zhendong; Zeng, Aiping; Zhang, Helong; Yu, Yan; Wei, Shihong; Li, Qingshan; Wang, Xiaojia; Wang, Xiangcai; Wang, Xiuwen; Yang, Runxiang; Dai, Xiumei; Bi, Minghong; Sun, Tao; Zhang, Qingyuan; Han, Cuicui; Li, Yujie; Kang, Xiaoyan; Liu, Yaxin; Zhang, Li

英文介紹

Biodrugs雜志英文介紹

An essential resource for R&D professionals and clinicians with an interest in biologic therapies.

BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease.

BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager?, supported by a database of international experts. This database is shared with other Adis journals.